The once lucrative heart-drug market is now poised to make a comeback, but at the cost of heavy investments in research and deal making.
After watching lower-priced generics seize sales of once-highflying blood-pressure, cholesterol and other heart drugs, companies struggled to discover replacements and then win reimbursement for five-figure prices. Drugmakers are now rolling out new medicines, though their commercial prospects are uncertain.
Vi har sammanfattat den här nyheten så att du kan läsa den snabbt. Om du är intresserad av nyheterna kan du läsa hela texten här. Läs mer: